reports
Novan Enters into Agreement to Sell Substantially All of its Assets, i...
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection – The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) continues, with Pre-Approval Inspection (PAI) complete and favorable mid-cycle review communication from FDA – – A...
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockh...
Novan to Provide Corporate Update at its 2023 Annual Meeting of Stockholders DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6, 2023 at 9:30 a.m. Eastern Time in a virtual format. The Company also announced that its Chairman, President and CEO, Paula Brown Stafford, will provide a corporate update on the Company after the conclusion of the ASM, including the Company’s current focus, position...
Novan Focuses Strategic Direction and Announces Restructuring
Novan Focuses Strategic Direction and Announces Restructuring – Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% – DURHAM, N.C., May 31, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that following an evaluation of its commercial and developmental stage assets, it has decided to ...
Novan Reports First Quarter 2023 Financial Results and Provides Corpor...
Novan Reports First Quarter 2023 Financial Results and Provides Corporate Update – Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., May 15, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the first quarter ended March 31, 2023, and provided a corporate update. The Company will host a conference call and webcast, today...
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Novan to Report First Quarter 2023 Financial Results on May 15, 2023 DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Interested...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Ne...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹ Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US1 Findings highlight impact on patient adherence of early onset of improvement with topical psoriasis medications1 WYNZORA® (calcipotriene and betamethasone dipropionate) Cream demonstrates rapid onset of action with results seen in efficacy, scale and itch as early as 1 week and continued improvement at 8 weeks2,3 DURHAM, N.C. and COPENHAGEN, Denmark, A...
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s ...
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD Live moderated webcast with members of the Novan management team and dermatological key opinion leader, Dr. Jeffrey Sugarman on Tuesday, April 25th at 2:00 PM ET DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD, on Tuesday, April 25, 2023, at ...
Novan Reports Full Year 2022 Financial Results and Provides Corporate ...
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update – Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., March 30, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the full year ended December 31, 2022 and provided a corporate update. The Company will host a conference call...
Novan to Report Full Year 2022 Financial Results on March 30, 2023
Novan to Report Full Year 2022 Financial Results on March 30, 2023 DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30th. Novan management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 a.m. ET that same day. The call will be led by Paula Brown Stafford, President and Chief Executive Officer of Novan, who will be joined by additional members of the Novan management team. Intere...
Novan Announces Closing of $6.0 Million Registered Direct Offering
Novan Announces Closing of $6.0 Million Registered Direct Offering DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and...
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference Presentation with live webcast today, March 14th at 10:40 AM ET DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33rd Annual Healthcare Conference today, March 14, 2023 at 10:40 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community wh...
Novan Announces $6.0 Million Registered Direct Offering
Novan Announces $6.0 Million Registered Direct Offering DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of (i) 5,042,017 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) warrants (the “Common Warrants”) to purchase up to 5,042,017 shares of common stock, at an effective combined purchase price of $1.19 per share (or pre-funded warrant) and associa...
Novan Moves Forward with Unified Corporate Branding
Novan Moves Forward with Unified Corporate Branding – Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of potential commercial launch of berdazimer gel, 10.3% (SB206) – DURHAM, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan. “Since the closing of our acquisition of EPI Healt...
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of...
FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024 – FDA completes filing review of application with no filing issues identified – – New Chemical Entity (“NCE”) has potential to be the first FDA-approved prescription product for molluscum in the U.S. – – Novan’s commercial team and sales force ready to prepare for launch of berdazimer gel, 10.3%, if approved – DURHAM, N.C., March 07, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that the U.S. Food ...
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Novan to Present at the Virtual Investor 2023 Companies to Watch Event Live video webcast on Thursday, January 19th at 12:00 PM ET DURHAM, N.C., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 12:00 PM ET. A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (novan.com). A webcast rep...
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel,...
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum – Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, most of them children1,2 – – Berdazimer gel, 10.3% has the potential to be the first FDA-approved prescription product for the treatment of molluscum3 – DURHAM, N.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” ...
EPI Health, a Novan Company, Enters into Exclusive License Agreement w...
EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE® in Japan DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”) granting Sato the right to develop, manufacture and market RHOFADE® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan. “Since 2017, our relationship with Sato has been a valuable co...
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreem...
EPI Health, a Novan Company, Executes a $15.0 Million Financing Agreement – Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritage Bank of Commerc...
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Derm...
Novan to Participate in the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & Medtech Conference – Paula Brown Stafford, President and Chief Executive Officer of Novan to participate in a live moderated panel discussion on Thursday, December 8th at 11:00 AM ET – DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will participate in a panel discussion titled, “Distraction or Destruction?: What’s New/Next in the Industry,” at the Ca...
Novan Reports Third Quarter 2022 Financial Results and Provides Corpor...
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update – Rhofade prescriptions increased 37% for third quarter year-to-date from prior year – – Continued progress toward submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeted around the end of 2022 – – Company to host conference call today at 8:30 a.m. ET – DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its financial and operating results for the third quarter ended September 30, 2022 and provided a corporat...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.